A New Rat Model of Epileptic Spasms Based on Methylazoxymethanol-Induced Malformations of Cortical Development

Eun-Hee Kim¹, Mi-Sun Yum²*,†, Minyoung Lee², Eun-Jin Kim², Woo-Hyun Shim³ and Tae-Sung Ko²*†

¹Department of Pediatrics, CHA Gangnam Medical Center, CHA University, Seoul, South Korea, ²Department of Pediatrics, Asan Medical Center Children's Hospital, University of Ulsan College of Medicine, Seoul, South Korea, ³Department of Radiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea

Malformations of cortical development (MCDs) can cause medically intractable epilepsies and cognitive disabilities in children. We developed a new model of MCD-associated epileptic spasms by treating rats prenatally with methylazoxymethanol acetate (MAM) to induce cortical malformations and postnatally with N-methyl-D-aspartate (NMDA) to induce spasms. To produce cortical malformations to infant rats, two dosages of MAM (15 mg/kg, intraperitoneally) were injected to pregnant rats at gestational day 15. In prenatally MAM-exposed rats and the controls, spasms were triggered by single (6 mg/kg on postnatal day 12 (P12) or 10 mg/kg on P13 or 15 mg/kg on P15) or multiple doses (P12, P13, and P15) of NMDA. In prenatally MAM-exposed rats with single NMDA-provoked spasms at P15, we obtain the intracranial electroencephalography and examine the pretreatment response to adrenocorticotropic hormone (ACTH) or vigabatrin. Rat pups prenatally exposed to MAM exhibited a significantly greater number of spasms in response to single and multiple postnatal NMDA doses than vehicle-exposed controls. Vigabatrin treatment prior to a single NMDA dose on P15 significantly suppressed spasms in MAM group rats (p < 0.05), while ACTH did not. The MAM group also showed significantly higher fast oscillation (25–100 Hz) power during NMDA-induced spasms than controls (p = 0.047). This new model of MCD-based epileptic spasms with corresponding features of human spasms will be valuable for future research of the developmental epilepsy.

Keywords: methylazoxymethanol acetate, malformations of cortical development, epileptic spasms, GABA, fast oscillations

INTRODUCTION

Malformations of cortical development (MCDs) often lead to developmental delay, intellectual disabilities, and intractable epilepsy (1). Both environmental injuries and genetic mutations can disrupt early brain development, giving rise to MCDs (2). Depending on MCDs severity and pattern, epilepsies may manifest at almost any developmental stage from newborns to adults and some
patients with MCDs present with epileptic spasms (3, 4). Several animal models have been generated to reproduce the pathologic characteristics of human MCDs for the investigation of the causal relationship between specific dysplastic lesions and functional abnormalities (5, 6). One such model is prenatal methyloxymethanol (MAM)-induced MCDs. The DNA alkylating agent MAM is administered to pregnant rats during the fetal period of intense neurogenesis to disrupt cell proliferation and migration of both neocortical and hippocampal pyramidal neurons (7, 8), and these abnormalities closely resemble those observed in patients with MCDs (9). Despite the vast evidence for hyper-excitability and decreased seizure threshold in malformed brain regions (7, 10–12), there is little evidence for spontaneous epilepsy in this MCD model (5, 13).

Malformations of cortical development are a major cause of catastrophic epileptic spasms such as epileptic spasms (3, 4, 14) and symptomatic epileptic spasms with MCDs have worse prognosis than those with cryptogenic or idiopathic etiologies (15). Epileptic spasms associated with MCDs are characterized by the coexistence of focal seizures and spasms as well as transition to refractory epilepsy, including Lennox–Gastaut syndrome (14). Thus, effective control of spasms during a critical period is believed to result in better developmental outcomes (16). Although there is no consensus regarding optimal treatment for epileptic spasms, the most commonly used medical therapies are adrenocorticotropic hormone (ACTH) and vigabatrin. ACTH is generally thought to offer an added advantage over vigabatrin particularly in cases with genetic or unknown etiologies, whereas vigabatrin has been shown to be effective in the short-term treatment in the patients with tuberous sclerosis complex and epileptic spasms (17).

To discover effective therapeutic strategies based on the pathomechanism in this intractable epilepsy, appropriate animal model of epileptic spasms is a prerequisite. However, currently available animal models of the epileptic spasms are mostly genetic models or models of cryptogenic or postnatal toxic etiologies (18), and there are no published data on the acute model of epileptic spasms associated with MCDs. We have developed a new infant rat model of epileptic spasms by combining prenatal MAM exposure (7, 8) and postnatal N-methyl-D-aspartic acid (NMDA) injection to induce age-specific spasms (19). We validated the anatomical and behavioral alterations in young rats with prenatal MAM exposure and the susceptibility to NMDA-induced spasms during infancy. To test the resemblance to human MCDs-associated spasms, the response to currently available AEDs was also evaluated. In addition, electrophysiological patterns during NMDA-induced spasms were examined to investigate the underlying neurophysiological abnormalities leading to enhanced seizure susceptibility in this model.

MATERIALS AND METHODS

Animals
All experiments were approved by the Institutional Animal Care and Use Committee of the Ulsan University College of Medicine and conducted in accordance with the Revised Guide for the Care and Use of Laboratory Animals [NIH GUIDE, 25(28), 1996]. Fourteen pregnant Sprague-Dawley dams (Orient Bio, Seongnam, Korea) were acquired on gestational day (G) 13 and housed individually in the animal facility during the remainder of their pregnancy under a 12-h light/dark cycle and aseptic conditions with free access to food and water. To produce MCDs, eight dams were administered two doses of 15 mg/kg MAM (MRIGlobal, Missouri) in 10 mL/kg saline at 0900 and 1800 hours on G15 by intraperitoneal (IP) injection. Six control pregnant rats were injected with saline vehicle. Delivery occurred consistently on G23, which was considered postnatal day (P) 0 for the offspring. Schematic depiction of experimental design and the rats used in each experiment are described in Figure 1 and Table 1.

In Vivo Proton Magnetic Resonance Imaging (MRI)
All proton (hydrogen-1 [1H])-MRI studies were conducted using a 9.4 T/160 mm Agilent animal MRI scanner (Agilent Technologies, Santa Clara, CA, USA) with 400 mT/m gradient system and a 38 mm 4-channel quadrature phased array coil for reception and 72 mm volume coil for transmission. During scanning, all animals were anesthetized by inhalation of 1.0% isoflurane in a 1:2 mixture of O2:N2O, and vital signs were monitored using a small-animal physiological monitoring device. 1H-MR images were acquired at P16 and P30 in the control (n = 4, 3 males and 1 female) and MAM-exposed rats (n = 5, 3 males and 2 females). T2-weighted images were acquired using a gradient echo sequence with the following imaging parameters: repetition time/echo time = 79/2.7 ms; flip-angle = 30°; 1 average; slice thickness (TH) = 2 mm; no inter-slice gap; field-of-view = 65 mm × 65 mm; matrix size = 128 × 128; receiver bandwidth = 50 kHz. To assess changes in cortical TH and hippocampal size in prenatally MAM-exposed and saline-exposed control rats, MRI data were analyzed using in-house software (AsanJ, Asan Medical Center, Seoul, Korea). Approximate anatomical positions were referenced relative to the bregma. The depths of the motor, somatosensory, and insular cortices in one coronal section (3.5 mm posterior from the bregma) and the area of both hippocampi in one coronal section (5.6 mm posterior from the bregma) were measured (Figure 2A).

Behavioral Testing
Behavioral experiments were performed in the control (n = 16, 10 males and 6 females) and MAM-exposed rats (n = 16, 9 males and 7 females) at P30 and P35–37. The rats were separated from their mother at P23. Each experiment was conducted in a standard behavioral testing room during the light phase (0800–2000 hours) of the 12-h light–dark cycle.

Open Field Test
On P30, subjects were placed in an open field apparatus consisted of a black plastic box (60 cm × 60 cm with walls 30 cm high) and spontaneous locomotive activity was recorded for 5 min using a ceiling-mounted video camera. Each animal was tested only once and the arena was cleaned with 70% alcohol between tests. The motor and resting activities in the periphery (15 cm from each wall) and central zones were automatically analyzed using motion-tracking software (SMART 3.0, Panlab. S.L.U., Spain). Total distance traveled and times spent in central and peripheral zones were determined.
TABLE 1 | Summary of number of rats used in each experimental procedure.

| Experimental group | MRI study | Behavior | EEG | Spasms susceptibility |
|--------------------|-----------|----------|-----|----------------------|
|                     | Saline-exposed rats (n = 50) |           |     |                      |
|                     | Saline injection (n = 16) | 4         | 16  | 10                   |
|                     | NMDA injection (n = 34) |           |     | 23                   |
|                     | MAM-exposed rats (n = 89) |           |     | 10 (1⁷)             |
|                     | Saline injection (n = 14) | 5         | 14  | 13 (1⁷)             |
|                     | NMDA injection (n = 75) |           |     | 62 (4⁴)             |

MRI, magnetic resonance imaging; EEG, electroencephalography; MAM, methylazoxymethanol acetate; NMDA, N-methyl-d-aspartate.

*Indicates the number of mortality case during the NMDA-induced spasms.

**Indicates the death associated with high dose vigabatrin and spasms.

Fear Conditioning

Fear conditioning procedures were performed using an observation chamber (25 cm x 25 cm x 25 cm, Panlab S.L.U., Barcelona, Spain) constructed of aluminum (two side walls and ceiling) and Plexiglas (rear wall and hinged front door) situated in a sound-proof box. The floor of the chamber consisted of 19 stainless steel rods (4 mm diameter) spaced 1.6 cm apart (center to center) connected to a shock generator and grid scrambler (Panlab S.L.U.) to deliver electrical footshocks. Both shock and conditions stimuli (CSs, tone and light) deliveries were controlled by a computerized system and rat behavior was recorded and analyzed using the signal generated by a high-sensitivity weight transducer system (Panlab S.L.U.). The chambers were cleaned with 70% alcohol between tests.

On P35, tone (cued) conditioning was performed as described previously (20). Conditioning consisted of a 2 min habituation period in the chamber followed by exposure to five pairings of a tone (CS; 30 s, 85 dB, 2,000 Hz) with light illumination ending with a footshock (0.8 mA, 2.0 s) and a 20 s silent interval. Contextual fear memory formation was evaluated by scoring freezing behavior (defined as complete immobility except respiration) for 5 min in the absence of the tone and foot shock at 24 h after the conditioning trial (P36). Cued fear responses to the CS were measured on P37. To reduce the influence of context, tactile, and visual cues were manipulated. Following a 2 min period with no CS, the rats were presented with five tones (85 dB, 2 kHz, 30 s; 20 s between tone presentations) in the absence of foot shock, and freezing activity was quantified.

Spasms Monitoring and Electroencephalography (EEG) Recording

In prenatally MAM- (n = 33, 17 males and 16 females) or saline- (n = 23, 12 males and 11 females) exposed rat pups, spasms were trigger by single dose (SD, 6 mg/kg on P12, 10 mg/kg on P13, or 15 mg/kg IP on P15, volume always 10 mL/kg in saline) or multiple doses (MD; P12, P13, and P15) of NMDA (Sigma, St. Louis, MO, USA) based on previous experiments (19, 21). The latency to onset of spasms (tail twisting and full spasms) and the total
number of full spasms were recorded. The rats were monitored for 90 min as our pilot experiments demonstrated that spasms would disappear within 90 min.

To evaluate the acute pretreatment effect of the current drug the prenatally MAM-exposed rats with spasms triggered by single NMDA dose at P15 were pretreated with ACTH \((n = 6, 6\) females, synthetic human ACTH; Abcam Biochemicals, Bristol, UK; 0.3 mg/kg in 10 mL/kg saline IP) or vigabatrin [VGB; Abcam Biochemicals, Bristol, UK; 125 mg/kg \((n = 11, 5\) males and 6 females) or 250 mg/kg \((n = 8, 2\) males and 6 females) in 10 mL/kg saline IP] at 30 min before the injection of NMDA according to the acute administration paradigm (19) and the total number and the latencies to onset of full spasms were compared with those of MAM-SD rats with saline vehicle \((n = 10, 3\) males and 7 females).

Twelve MAM-exposed rat pups \((7\) males and 5 females) and ten saline-exposed controls \((4\) males and 6 females) were used for intracranial EEG. For EEG recordings, electrodes were surgically implanted in P13 pups while under sedation with ketamine/xylazine (50/7 mg/kg in 10 mL/kg saline IP). Two silver recording electrodes were implanted over both parietal cortices, while reference and ground lead screws were positioned above the cerebellum and near the bregma, respectively. The electrodes were connected to a multiple socket and secured to the skull with dental acrylic. At P15, EEGs of the two groups of rats were monitored with simultaneous and synchronized video using the Twin EEG system (Grass Technologies) for 1 h before NMDA injection and 2 h after injection or until the end of spasms. The sampling rate was 400 Hz and signals were bandpass filtered at 0.1–100 Hz. The intensity and the frequency distribution of the EEG were obtained from the power spectrum by fast Fourier Transform with a block size of 256. The absolute power \((\mu V^2)\) of each EEG frequency band [delta and theta (0.5–7 Hz), alpha (8–12 Hz), beta (13–24 Hz), and fast oscillations (FOs) (25–100 Hz)] at selected pre-NMDA resting periods (background activity) and during post-NMDA spasms and inter-spasms periods were recorded and compared between MAM and control rats. Color density spectral arrays (CDSAs) are used to display the FOs. Each CDSA trace.
contains 30 s of condensed EEG data from 25 to 100 Hz on the y-axis with color scale for power.

Statistical Analyses
All data were analyzed using IBM SPSS (ver. 22.0; IBM Corp., Armonk, NY, USA). Group differences were assessed using the Kruskal–Wallis test, the Mann–Whitney U test, or independent t-test and appropriate Bonferroni correction was applied for multiple pair-wise comparisons to maintain an alpha level of $p < 0.05$. Repeated-measure ANOVA was used to analyze the effects of group and age on spasm susceptibility. In spectral analysis of EEG data (power vs. frequency), the random effect model was used to adjust for heterogeneity among EEG power values for each subject. A $p$ value <0.05 was considered statistically significant.

RESULTS

In Vivo Structural Abnormalities in MAM-Exposed Rats during Infancy and Juvenile Period

Figure 2 presents representative T2-weighted MR images of control $(n = 4)$ and MAM-exposed rats $(n = 5)$ acquired on P16 and P30. Compared to the normal brain of controls, MAM-exposed rats exhibited widespread cortical thinning, enlargement of lateral and third ventricles, and volume reduction and dysplasia of bilateral hippocampi and amygdalas at both P16 and P30 (Figure 2B). MAM group rats exhibited reduced mean TH of motor cortex (P16, control vs. MAM; 16.0 ± 0.3 mm; P30, 1.0 ± 0.05 vs. 1.1 ± 0.02 mm; $p = 0.016$ for both), somatosensory cortex (P16, 1.7 ± 0.04 vs. 1.4 ± 0.04 mm; P30, 1.8 ± 0.06 vs. 1.4 ± 0.02 mm; $p = 0.016$ for both), and insular cortex (P16, 1.7 ± 0.03 vs. 1.2 ± 0.04 mm; P30, 1.5 ± 0.04 vs. 1.2 ± 0.02 mm; $p = 0.016$ for both). Compared to controls, the mean areas of bilateral hippocampi were also significantly reduced in MAM-exposed rats at both P16 and P30 (P16, 15.6 ± 0.3 vs. 12.2 ± 0.3 mm$^2$; P30, 21.7 ± 0.8 vs. 15.1 ± 0.4 mm$^2$; $p = 0.016$ for both) (Figure 2E).

Behavioral Abnormalities in MAM-Exposed Young Rats

Results of the open field test at P30 for MAM-exposed rats $(n = 14)$ and saline-exposed controls $(n = 16)$ are presented in Figures 3A,B. The mean ambulation distances in peripheral and central zones did not differ significantly between groups (Figure 3A), but the mean speed in the central zone was significantly slower in the MAM group compared to controls $(5.2 ± 0.9$ vs. $9.8 ± 1.1$ cm/s; $p = 0.016$) (Figure 3B).

The duration of freezing during conditioning on P35 and the freezing response to context on P36 did not differ significantly between groups. However, the freezing response to conditioned sound stimuli (freezing during sound ON) was significantly shorter in MAM-exposed rats than controls $(100.5 ± 9.6$ vs. $124.8 ± 7.7$ s, $n = 16$ and 12, respectively, $p = 0.047$) with significantly reduced freezing duration to sound cue on the eighth session of P37 $(18.8 ± 3.0$ vs. $26.0 ± 1.2$ s, $p = 0.042$) (Figures 3C,D).

Elevated NMDA-Induced Spasm Susceptibility in MAM-Exposed Infant Rats

After NMDA injection, the rats were motionless for 10 min and subsequently became hyperactive and displayed frequent tail twisting (tailing) followed by moving around in circles. Eventually, the rat developed spasms manifesting clusters of hyperflexion of whole body, which are very similar to the human condition and a previous animal model (19, 22). The number of full spasms triggered by a single NMDA dose was significantly higher in MAM-exposed rats (MAM-SD) compared to age-matched controls (control-SD) at P12 $(65.3 ± 6.2$ vs. $35.1 ± 5.9$, $n = 9$ vs. $n = 15$; $p = 0.003$) and P13 $(18.8 ± 3.8$ vs. $4.4 ± 1.2$, $n = 8$ in both groups; $p = 0.002$) but not P15 $(42.7 ± 6.4$ vs. $39.8 ± 4.8$, $n = 6$ vs. $n = 10$; $p = 0.958$) (Figure 4A). The MAM-SD rats also demonstrated significantly shorter latency to tailing onset at P13 than controls-SD rats $(966.6 ± 49.6$ vs. $1,532.6 ± 124.5$ s, $p < 0.001$), and the latency to onset of full spasms was not significantly different (Figure 4B). In experiments using multiple NMDA administrations, a significantly greater number of full spasms was observed following each administration in the MAM group (MAM-SD) compared to controls (control-SD) at P12 $(65.3 ± 6.2$ vs. $35.1 ± 5.9$, $p = 0.003$), P13 $(80.1 ± 7.2$ vs. $31.7 ± 3.2$, $p = 0.001$), and P15 $(74.5 ± 10.1$ vs. $29.6 ± 6.0$, $p = 0.002$) (Figure 4C). The latency to onset of full spasms following exposure to multiple NMDA doses also differed significantly between control-SD and MAM-SD rats with a significant group × time interaction (interaction $p = 0.032$) (Figure 4D). The mean latency to onset of full spasms in MAM-SD rats was significantly shorter compared to controls at P13 $(1313.7 ± 57.6$ vs. $1543.8 ± 78.3$ s, $p = 0.03$).

Acute pretreatment with 125 mg/kg vigabatrin (VGB125, $n = 11$) or 250 mg/kg (VGB250, $n = 8$) significantly reduced the number of spasms induced by a single NMDA dose at P15 in MAM-exposed rats compared to VGB-naive MAM-exposed rats (VGB125, 8.8 ± 2.6 vs. $42.7 ± 6.4$, $p < 0.001$; VGB250 4.3 ± 1.0, $p < 0.001$; $n = 10$ drug-naive rats) (Figure 4E). In addition, acute pretreatment with VGB125 or VGB250 significantly prolonged the mean latency to onset of tailing compared to controls (VGB125, 1,404.8 ± 70.5 vs. $1,091.5 ± 80.7$ s, $p = 0.01$; VGB250, 1,660.4 ± 113.8 s, $p = 0.001$) and delayed the onset of the full spasm (VGB125, 2,047.8 ± 153.5 vs. $1,480.9 ± 82.1$ s, $p = 0.012$; VGB250, 2,246.9 ± 398.3 s, $p = 0.016$) (Figure 4F). In contrast, acute pretreatment with ACTH had little effect on the number of spasms and the latency to onset of spasms.

Stronger FOs in MAM-Exposed Infant Rats

Representative EEG recordings (upper panel) and corresponding CDSAs (lower panel) of pre-NMDA resting periods and post-NMDA spasms and inter-spasms periods are presented in Figure 5. After NMDA administration, both MAM and control rats treated with a single NMDA dose exhibited frequent spikes intermixed with high amplitude slow wave activity during inter-spasms periods. The corresponding CDSAs revealed more noticeable FOs in the 25–100 Hz range during post-NMDA inter-spasms period compared to pre-NMDA background activity (Figures 5C,D). The EEGs during single-dose

Frontiers in Neurology | www.frontiersin.org 5 June 2017 | Volume 8 | Article 271
NMDA-induced spasms showed low-amplitude fast activities in both groups, while the corresponding CDSAs in the MAM group revealed more prominent FOs in the 25–100 Hz range (Figures 5E,F).

Quantitative measure of power spectra derived from these EEGs were compared between control-SD (n = 9) and the MAM-SD rats (n = 9) (Figure 6). Before NMDA administration, there were no significant differences in EEG band powers between groups. Both groups showed significantly higher EEG powers (µV^2) at delta and theta (0.5–7 Hz) and alpha (8–12 Hz) frequency bands during post-NMDA inter-spasms periods than during pre-NMDA periods (controls at 0.5–7 Hz: 3,535.7 ± 1,642.9 vs. 21,637.2 ± 5,235.5 µV^2, p = 0.001; MAMS at 0.5–7 Hz: 5,879.7 ± 2,112.3 vs. 27,841.4 ± 5,784.0 µV^2, p < 0.001; controls at 8–12 Hz: 9,855.8 ± 2,666.9 vs. 50,805.1 ± 10,103.5 µV^2, p < 0.001; MAMS at 8–12 Hz: 9,119.2 ± 1,804.8 vs. 47,678.1 ± 8,162.4 µV^2, p < 0.001) (Figures 6A,B). However, only the MAM group showed a significant increase in beta power (13–24 Hz) and FO (25–100 Hz) power during post-NMDA inter-spasms periods (13–24 Hz: 10,247.47 ± 2,693.17 vs. 3,108.16 ± 662.30 µV^2, p < 0.001; 25–100 Hz: 7,158.45 ± 1,469.59 vs. 4,246.30 ± 717.46 µV^2, p = 0.005) than pre-NMDA periods (Figures 6C,D). During post-NMDA spasms, MAM-SD rats showed significantly higher FO power than control-SD rats (5,264.1 ± 350.7 vs. 3,994.8 ± 327.2 µV^2, p = 0.029) (Figure 6D).

**DISCUSSION**

Cortical malformations are common etiologies of refractory epilepsy, and epileptic spasms are frequently associated with this pathological condition (23). Here, we characterized MAM-induced MCDs in young rats in vivo and established a new infant rat model of epileptic spasms based on the combination of chemically induced MCDs and postnatal NMDA administration.

The MAM treatment protocol could reproduce the anatomical disruptions observed in previous studies of adult rats (8, 24) in infant rats, which was confirmed by in vivo MRI. Open-field behavior and fear-associated learning and memory were also altered in this animal model at younger ages than previously shown (25, 26). The reduced ambulation speed in the central zone of the open field can be interpreted as reduced anxiety as rats with normal anxiety prefer to stay in the periphery (27). The fear responses are associated with hippocampus- and amygdala-dependent emotional learning and memory (28) and the altered anxiety/fear-associated memory in this MCD model may be
related to pathological changes in the hippocampus and amygdala (29). In contrast, multiple bouts of NMDA-induced spasms in this study did not have a significant impact on these behavioral parameters (data not shown) suggesting that the underlying MCDs are the primary factor leading to cognitive impairment in accordance with a previous study (26).

Based on the well-characterized MAM model of MCDs and a previously reported model of epileptic spasms (19), we tested the
susceptibility of MCD rats to NMDA-provoked epileptic spasms. MAM-exposed infant rats exhibited increased susceptibility to spasms triggered by both single and multiple doses of NMDA with larger (higher power) FOs during spasms and inter-spasms periods compared to controls. Based on intra-operative recordings of patients with cortical malformation-associated epilepsy, it is well established that malformed brain regions are potential sites of seizure generation with dense FOs (30). Studies of MAM-exposed rats also indicated a lower threshold for generation of epileptiform activity (7, 11, 12). This higher seizure propensity may explain the increased number of spasms during infancy in our model. The age-specific difference in spasm susceptibility observed in MAM-exposed rats following a single NMDA dose also suggests a parallel age-dependent change in neuronal or network excitability. Indeed, susceptibility to seizures changes over the postnatal development with the development of neural circuits (31, 32). The immature MCD brain may exhibit a time window of over-excitation during development, which appeared to be at P12–P13 in our model based on peak NMDA response. In addition, earlier spasms in prenatally MAM-exposed rats increased subsequent spasms susceptibility as previously reported in prenatal betamethasone-exposed rats (22) suggesting
that post-spasm neuronal network changes further lower spasms threshold.

Fast oscillations (>50 Hz) during epileptic spasms are generated by the neocortex and could be a biomarker of the ictal focus (33). Previous studies also reported the presence of abnormally increased FOs in ictal and interictal periods with epileptic spasms in human patients and animal models (33, 34). In the present study, we found that rats with MCDs showed higher power FOs (25–100 Hz) during spasms and inter-spasms periods compared to controls, which may reflect increased epileptogenicity of the malformed cortex.

The efficacies of ACTH and VGB, which are treatments of choice for the human condition (35), were also tested against NMDA-induced spasms in this model. While acute ACTH pretreatment had no impact on NMDA-induced spasms, acute VGB pretreatment significantly suppressed their development consistent with previous studies in other animal models of symptomatic epileptic spasms (18). Considering the good therapeutic effects of acute pretreatment with ACTH on the suppression of spasms in animal models of cryptogenic epileptic spasms (19), it is possible that different underlying etiology of spasms may explain the different responses to ACTH. On the other hand, a deficit in GABAergic inhibition found in animal models of MCDs (11, 12, 36) could account for the good response to VGB. Recent evidence suggests that changes in GABAergic transmission contribute to the abnormal excitability in cortical dysplasia (37). The disruption of GABAergic system in seizures associated with cortical malformation is also supported by the particular efficacy of the GABA transaminase inhibitor VGB against epileptic spasms in tuberous sclerosis complex (35), which shares certain pathophysiological traits with MCDs (38). Thus, the VGB sensitivity of this new model of epileptic spasms validates again its analogy to human epileptic spasms due to MCDs and suggests the putative mechanisms involved in epileptogenesis of epileptic spasms associated with MCDs.

A significant advantage of this model over spontaneous seizure models is that we can trigger spasms at specific times for examination during the rat infancy. This model also has structural and electrophysiological features of MCDs-associated epileptic spasms in humans. Although two-channel EEG data are not sufficient to document the disorganization and multifocality of hypsarrhythmia, high amplitude fast activities similar to the
previous report with NMDA-induced spasms (19) are shown and
the difference between the two models with different structures
are analyzed. In future studies with this model, alterations of
cytoarchitectures and neurometabolites should be investigated to
find the pathomechanism of spasms susceptibility in MCDs,
which will enable the development of new targeted therapy. In
addition, this model can be used as the preclinical tests for the
new antiepileptic drugs.

In conclusion, the present study provides an important valida-
tion of a new model of epileptic spasms with underlying MCDs
pathology. MCDs were confirmed in young rats by in vivo MRI.
Postnatal NMDA administration produced more intense spasms
with stronger FOs compared to controls. The efficacy of VGB
for suppression of spasms in this rat model was comparable to
that against human epileptic spasms with structural etiologies.
Therefore, this model may provide further insights into the
pathogenesis, progression, and clinical features of epileptic
ecephalopathies associated with MCDs and hold great promise
as a substrate to identify novel therapeutic targets for this devas-
tating disorder.

ETHICS STATEMENT

All experiments were approved by the Institutional Animal
Care and Use Committee of the Ulsan University College of
Medicine and conducted in accordance with the Revised Guide
for the Care and Use of Laboratory Animals [NIH GUIDE,
25(28), 1996].

AUTHOR CONTRIBUTIONS

E-HK, M-SY, and T-SK were involved in the conception and
design of the study. E-HK, M-SY, ML, E-JK, and W-HS were
involved in data acquisition and data interpretation for the
study. E-HK and M-SY were involved in drafting and editing the
manuscript and the figures. M-SY and T-SK reviewed submitted
version of manuscript and supervised the study.

ACKNOWLEDGMENTS

We gratefully acknowledge technical support from Biomedical
Imaging Infrastructure, Department of Radiology, Asan Medical
Center.

FUNDING

This study was funded by Basic Science Research Program through
the National Research Foundation of Korea (NRF) funded by the
Korean Government Ministry of Science, ICT and Future
Planning (NRF-2016R1C1B2010078) and by a grant 2014-0123
from the Asan Institute for Life Sciences, Asan Medical Center,
Seoul, Korea.

REFERENCES

1. Blumcke I, Vinters HV, Armstrong D, Aronica E, Thom M, Spreafico R. Malformations of cortical development and epilepsies: neuropathological
findings with emphasis on focal cortical dysplasia. Epileptic Disord (2009)
11(3):181–93. doi:10.1684/epd.2009.0261

2. Poretti A, Boltschauer E, Huissman TA. Congenital brain abnormalities: an
update on malformations of cortical development and infratentorial malfor-
mations. Semin Neurol (2014) 34(3):239–48. doi:10.1055/s-0034-1386762

3. Osborne JP, Lux AL, Edwards SW, Hancock E, Johnson AL, Kennedy
CR, et al. The underlying etiology of infantile spasms (West syndrome):
information from the United Kingdom Infantile Spasms Study (UKISS) on
contemporary causes and their classification. Epilepsia (2010) 51(10):2168–74.
doi:10.1111/j.1528-1167.2010.02695.x

4. Kuzniecky R. Epilepsy and malformations of cortical development:
new developments. Curr Opin Neurol (2015) 28(2):151–7. doi:10.1097/
WCO.0000000000000175

5. Wong M. Animal models of focal cortical dysplasia and tuberous sclerosis
complex: recent progress toward clinical applications. Epilepsy Res
(2015) 120(1):29–44. doi:10.1016/j.eplepsyres.2015.08.005

6. Colacitti C, Sancini G, DeBlasi S, Franceschetti S, Caputi A, Frassoni C,
et al. Prenatal methylazoxymethanol treatment in rats produces brain
abnormalities with morphological similarities to human developmen-
tal brain dysgeneses. J Neuropathol Exp Neurol (1999) 58(1):92–106.
doi:10.1097/00005072-199901000-00010

7. Lodge DJ, Grace AA. Gestational methylazoxymethanol acetate administra-
tion: a developmental disruption model of schizophrenia. Behav Brain Res
(2009) 204(2):306–12. doi:10.1016/j.bbr.2009.01.031

8. Colacitti C, Sancini G, DeBlasi S, Franceschetti S, Caputi A, Frassoni C,
et al. Prenatal methylazoxymethanol treatment in rats produces brain
abnormalities with morphological similarities to human developmen-
tal brain dysgeneses. J Neuropathol Exp Neurol (1999) 58(1):92–106.
doi:10.1097/00005072-199901000-00010

9. Lodge DJ, Grace AA. Gestational methylazoxymethanol acetate administra-
tion: a developmental disruption model of schizophrenia. Behav Brain Res
(2009) 204(2):306–12. doi:10.1016/j.bbr.2009.01.031

10. Germano IM, Spersber EF. Increased seizure susceptibility in adult rats with
neural migration disorders. Brain Res (1997) 777(1–2):219–22. doi:10.1016/
S0006-8993(97)01022-6

11. Marin O. Interneuron dysfunction in psychiatric disorders. Nat Rev Neurosci
(2012) 13(2):107–20. doi:10.1038/nrn3155

12. Colciaghi F, Finardi A, Frasca A, Balossi S, Nobili P, Carriero G, et al. Status
epilepticus-induced pathologic plasticity in a rat model of focal cortical
dysplasia. Brain (2011) 134(Pt 10):2828–3. doi:10.1093/brain/awr045

13. Harrington EP, Model G, Najim IM, Baraban SC. Altered glutamate
receptor – transporter expression and spontaneous seizures in rats
exposed to methyloxazometanol in utero. Epilepsia (2007) 48(1):158–68.
doi:10.1111/j.1528-1167.2006.00838.x

14. Kobayashi K, Ohtsuka Y, Ohno S, Ohmori I, Ogino T, Yoshinaga H, et al.
Clinical spectrum of epileptic spasms associated with cortical malformation.
Neuropediatrics (2001) 32(5):236–44. doi:10.1055/s-2001-19117

15. Ruikonen RS. Favourable prognostic factors with infantile spasms. Eur J
Paediatr Neurol (2010) 14(1):13–8. doi:10.1016/j.ejpn.2009.03.004

16. Caplan R, Siddarth P, Matherh G, Vinters H, Curtiss S, Levitt J, et al. Developmental outcome with and without successful intervention. Int Rev
Neurobiol (2002) 49:269–84. doi:10.1016/S0074-7742(02)49017-4

17. Wilmshurst JM, Gaillard WD, Vinayan KP, Tsuchida TN, Plouin P, Van
Bogaert P, et al. Summary of recommendations for the management of infantile
seizures: Task Force Report for the ILAE Commission of Pediatrics. Epilepsia
(2015) 56(8):1185–97. doi:10.1111/epi.13057

18. Galanopoulou AS, Moshe SL. Pathogenesis and new candidate treatments
for infantile spasms and early life epileptic encephalopathies: a view
from preclinical studies. Neurobiol Dis (2015) 79:135–49. doi:10.1016/j.
nbdis.2015.04.015

19. Velese I, Jehe K, Asche S, Velskova J. Model of infantile spasms induced
by N-methyl-D-aspartic acid in prenatally impaired brain. Ann Neurol
(2007) 61(2):109–19. doi:10.1002/ana.21082

20. Yum MS, Lee M, Woo DC, Kim DW, Ko TS, Velisek L, beta-Hydroxybutyrate
attenuates NMDA-induced spasms in rats with evidence of neuronal stabilis-
tion on MR spectroscopy. Epilepsy Res (2015) 117:125–32. doi:10.1016/j.
epilepsres.2015.08.005
21. Velisek L, Chachua T, Yum MS, Poon KL, Veliskova J. Model of cryptogenic infantile spasms after prenatal corticosteroid priming. Epilepsia (2010) 51(Suppl 5):S45–9. doi:10.1111/j.1528-1167.2010.02630.x
22. Chachua T, Yum MS, Veliskova J, Velisek L. Validation of the rat model of cryptogenic infantile spasms. Epilepsia (2011) 52(9):1666–77. doi:10.1111/j.1528-1167.2011.03220.x
23. Shain C, Ramgopal S, Falill Z, Parulkar I, Knowlton R, et al. Polymicrogyria-associated epilepsy: a multicenter phenotypic study from the Epilepsy Phenome/Genome Project. Epilepsia (2013) 54(8):1368–75. doi:10.1111/epi.12238
24. Chin CL, Curzon P, Schwartz AJ, O’Sullivan EM, Rueter LE, Fox GB, et al. Structural abnormalities revealed by magnetic resonance imaging in rats prenatally exposed to methylazoxymethanol acetate parallel cerebral pathology in schizophrenia. Synapse (2011) 65(5):393–403. doi:10.1002/syn.20857
25. Gastambide F, Taylor AM, Palmer C, Svard H, Karjalainen M, Janhunen SK, et al. Alterations in spatial memory and anxiety in the MAM E17 rat model of hippocampal pathology in schizophrenia. Psychopharmacology (2015) 232(21–22):4099–112. doi:10.1007/s00213-014-3862-1
26. Lucas MM, Lenck-Santini PP, Holmes GL, Scott RC. Impaired cognition in rats with cortical dysplasia: additional impact of early-life seizures. Brain (2011) 134(Pt 6):1684–93. doi:10.1093/brainawr087
27. Belzung C, Griebel G. Measuring normal and pathological anxiety-like behaviour in mice: a review. Behav Brain Res (2001) 125(1–2):141–9. doi:10.1016/S0166-4328(01)00291-x
28. Curzon P, Rustay NR, Brown KE. Cued and contextual fear conditioning for rodents. 2nd ed. In: Buccafusco JJ, editor. Methods of Behavior Analysis in Neuroscience. Boca Raton, FL: Frontiers in Neuroscience (2009).
29. McNaughton N, Corr PJ. A two-dimensional neuropsychology of defense: fear/anxiety and defensive distance. Neurosci Biobehav Rev (2004) 28(3):285–305. doi:10.1016/j.neubiorev.2004.03.005
30. Duchowny M. Clinical, functional, and neurophysiologic assessment of dysplastic cortical networks: implications for cortical functioning and surgical management. Epilepsia (2009) 50(Suppl 9):19–27. doi:10.1111/j.1528-1167.2009.02291.x
31. Veliskova J, Claudio OI, Galanopoulou AS, Lado FA, Ravizza T, Velisek L, et al. Seizures in the developing brain. Epilepsia (2004) 45(Suppl 8):6–12. doi:10.1111/j.0013-9580.2004.458002.x
32. Rakhade SN, Jensen FE. Epileptogenesis in the immature brain: emerging mechanisms. Nat Rev Neurol (2009) 5(7):380–91. doi:10.1038/nrneurol.2009.80
33. Nariai H, Matsuzaki N, Juhasz C, Nagasawa T, Sood S, Chugani HT, et al. Ictal high-frequency oscillations at 80–200 Hz coupled with delta phase in epileptic spams. Epilepsia (2011) 52(10):e130–4. doi:10.1111/j.1528-1167.2011.03263.x
34. Frost JD Jr, Lee CL, Hrachovy RA, Swann JW. High frequency EEG activity associated with ictal events in an animal model of infantile spasms. Epilepsia (2011) 52(1):33–62. doi:10.1111/j.1528-1167.2010.02887.x
35. Hancock EC, Osborne JP, Edwards SW. Treatment of infantile spasms. Cochrane Database Syst Rev (2013) 6:CD001770. doi:10.1002/14651858.CD001770.pub3
36. Benardete EA, Kriegstein AR. Increased excitability and decreased sensitivity to GABA in an animal model of dysplastic cortex. Epilepsia (2002) 43(9):970–82. doi:10.1046/j.1528-1157.2002.04091.x
37. Cepeda C, Chen JY, Wu JY, Fisher RS, Vinters HV, Mathern GW, et al. Pacemaker GABA synaptic activity may contribute to network synchronization in pediatric cortical dysplasia. Neurobiol Dis (2014) 62:208–17. doi:10.1016/j.nbd.2013.10.001
38. Crino PB. mTOR signaling in epilepsy: insights from malformations of cortical development. Cold Spring Harb Perspect Med (2015) 5(4). doi:10.1101/cshperspect.a022442

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2017 Kim, Yum, Lee, Ko. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.